drug
(avibactam sodium + aztreonam)
Marketedupdated 6mo agoby $ABBV AbbVie Inc.
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Patent cliff
source: FDA Orange Bookfirst barrier falls
Feb 7, 2028
~1.2 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (7)
- Jun 15, 2032compositionUS 8969566
- Jun 15, 2032compositionUS 9284314
- Jun 15, 2032compositionUS 9695122
- Aug 12, 2031compositionUS 84710254.7y
- Oct 8, 2030formulationUS 88354553.9y
- Nov 12, 2026formulationUS 7612087
- Jan 7, 2026compositionUS 7112592
FDA exclusivities (2)
- Feb 7, 2033GAINGAIN Antibiotic (5y)
- Feb 7, 2028NPNP1.2y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that